SPICA THERAPEUTICS

Spica Therapeutics is a pioneering biotech company operating in Denmark and Belgium that aims to deliver disease-modifying, antibody-based therapeutics for chronic diseases. 

Using its proprietary Macrophage Fingerprinting Platform, Spica identifies and therapeutically targets disease-driving, pathogenic macrophage subpopulations to restore healthy cellular function and transform treatment in cancer, fibroinflammatory, and autoimmune diseases.   

In 2025, Spica Therapeutics entered into a strategic collaboration with VUB and VIB, and was officially reported as a VUB spin-off. VUB has licensed IP rights to Spica.

Through this partnership, Spica works closely with the Molecular Imaging and Therapy (MITH) research group at VUB, led by Prof. Nick Devoogdt. Renowned for pioneering work in the development and bench-to-bedside translation of radiotracers to noninvasively image cancer and immune cells, the MITH lab—along with the Brussels Center for Immunology (BCIM), under Prof. Jo Van Ginderachter’s leadership—brings vital imaging and diagnostic expertise to the table. Together with Prof. Jo Van Ginderachter’s team at VIB, renowned for their work on the role of myeloid cells (mostly macrophages) in cancer and infectious diseases, this collaboration aims to accelerate the development of Spica’s therapeutic pipeline.